

AMENDMENTS TO THE CLAIMS UNDER REVISED 37 C.F.R. § 1.121

Please cancel Claims 25-30 and 34-38. Please add new claims 39-58. Please amend the claims as follows:

1-32. (Canceled)

33. (Currently amended) A composition comprising:

a) HIV infected cells that have been treated with hyaluronidase, and

b) optionally a pharmaceutically acceptable carrier or diluent,

wherein the HIV infected cells have been treated with hyaluronidase at a toxic concentration.

34-38. (Canceled)

39. (New) The composition of claim 33 wherein the HIV infected cells have been treated with Wydase® or a hyaluronidase enzyme with equivalent activity at a concentration of at least .01611 units/mL.

40. (New) The composition of claim 33 wherein the HIV infected cells are human host cells.

41. (New) The composition of claim 40 wherein the HIV infected cells are human peripheral blood mononuclear cells or antigen presenting cells.

42. (New) The composition of claim 40 wherein the HIV infected cells exhibit reduced cell viability.

43. (New) The composition of claim 42 wherein the HIV infected cells form HIV immunogens.

44. (New) The composition of claim 43 wherein the immunogens prime and activate antigen presenting cells.

45. (New) The composition of claim 44 wherein the antigen presenting cells are macrophages, monocytes or both.
46. (New) The composition of claim 45 wherein the antigen presenting cells are capable of engendering an immune response that imparts to naïve cells resistance to HIV challenge.
47. (New) The composition of claim 45 wherein the antigen presenting cells are capable of transferring HIV immunity to naïve cells following co-incubation with the treated cells.
48. (New) A composition comprising:
a) HIV infected cells that have been treated with hyaluronidase, and
b) optionally a pharmaceutically acceptable carrier or diluent,
wherein the HIV infected cells have been treated with hyaluronidase for more than one day.
49. (New) The composition of claim 48 wherein the HIV infected cells have been treated with hyaluronidase for more than six days.
50. (New) The composition of claim 48 wherein the HIV infected cells exhibit reduced cell viability.
51. (New) A composition comprising:
a) HIV infected cells that have been treated with hyaluronidase, and
b) optionally a pharmaceutically acceptable carrier or diluent,
wherein the HIV infected cells have been treated with a toxic concentration of hyaluronidase for more than one day.
52. (New) The composition of claim 51 wherein the HIV infected cells have been treated with hyaluronidase for more than six days.

53. (New) The composition of claim 51 wherein the HIV infected cells have been treated with Wydase® or a hyaluronidase enzyme with equivalent activity at a concentration of at least .01611 units/mL.

54. (New) A composition comprising:

a) HIV infected cells that have been treated with hyaluronidase, and

b) optionally a pharmaceutically acceptable carrier or diluent,

wherein the cells form HIV immunogens or antigens that prime and activate antigen presenting cells.

55. (New) The composition of claim 54 wherein the HIV infected cells are human host cells.

56. (New) The composition of claim 54 wherein the Antigen Presenting Cells are capable of engendering an immune response that imparts to naïve cells resistance to HIV challenge.

57. (New) A composition comprising:

a) HIV infected cells that have been treated with hyaluronidase, and

b) optionally a pharmaceutically acceptable carrier or diluent,

wherein the HIV infected cells exhibit reduced cell viability.

58. (New) The composition of claim 57 wherein the HIV infected cells form HIV immunogens.